权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Treatment of glandma. Role of optic nerve head and cheroidal circulation

腺体的治疗。

基本信息

批准号：
07457410
负责人：
ARAIE Makoto
金额：
$ 4.29万
依托单位：
University of Tokyo
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
1995
资助国家：
日本
起止时间：
1995 至 1996
项目状态：
已结题

项目摘要

A quantitative index of tissue blood flow velocity and blood flow measured by laser speckle method (NB) in the optic nerve head (NB_<ONH>) and choroid (NB_<CH>) were determined in experimental animals and normal human volunteers before and after administration of several antiglaucoma drugs which have been clinically used or were under development.Animal study : In albino rabbits, effects of twice daily 2-3 week instillation of 0.5% betaxolol, a beta-1 blocker, 0.5% timolol, a beta-1,2 blocker, 2% carteolol, a beta-1,2 blocker with intrinsic sympathomimetic activity, 0.25% nipradilol, a beta-1,2 blocker alpha-1 blocking activity, and 0.05% bunazosin, an alpha-1 blocker, were studied. Topical unilateral carteolol increased NB_<ONH> in both eyes, while topical unilateral timolol, betaxolol and nipradilol increased it only in ipsilateral eye. Topical unilateral bunazosin showed no effect in both eyes. Intravenous injection of a calcium antagonist, nilvadipine, nicardipine or semothiazil, increased NB_<CH>, while NB_<ONH> was increased only by nilvadipine. To carry out experiments in monkeys, specially disigned monkey chair was first constructed. In experimental glaucoma monkey eyes, oral planidipine, another calsium antagonist, however, showed no significant effect on NB_<ONH>.Human study : Twice daily 3-week unilateral instillation of 0.5% carteolol slightly increased NB_<ONH> in both eyes, while that of 0.5% betaxolol slightly increased it only in ipsilateral eye and that of 0.5% timolol showed no effect in both eyes. Oral nilvadipine, but not semothiazil, increased in NB_<ONH> humans.These results indicate that some beta-blockers can affect optic nerve head circulation when given topically and that some calcium antagonist can increase optic nerve head blood flow, which may have implications in treating glaucoma or in studying pathogenesis of glaucoma.

应用激光散斑法（NB）<ONH><CH>测定了实验动物和正常志愿者在服用几种已临床应用或正在研制的抗青光眼药物前后的视神经乳头（NB_1）和脉络膜（NB_2）组织血流速度和血流量的定量指标。在白化病兔中，每天两次滴注0.5%倍他洛尔（一种β-1阻滞剂）、0.5%噻吗洛尔（一种β-1，2阻滞剂）、2%卡替洛尔（一种β-1，研究了具有内在拟交感神经活性的2受体阻滞剂、0.25%尼普拉地洛（一种β-1，2受体阻滞剂α-1受体阻滞剂）和0.05%布那唑嗪（一种α-1受体阻滞剂）。局部单侧卡替洛尔增加双眼的NB_<ONH>，而局部单侧噻吗洛尔、倍他洛尔和尼普拉洛尔仅增加同侧眼的NB_。局部单侧布那唑嗪对双眼无影响。静脉注射钙拮抗剂尼伐地平、尼卡地平或西莫噻嗪可增加NB_<CH>，而NB_<ONH>仅由尼伐地平增加。为了在猴子身上进行实验，首先建造了专门设计的猴子椅。在实验性青光眼猴眼，口服钙拮抗剂普拉地平对NB_（1/2）无明显影响<ONH>。人眼实验：0.5%卡替洛尔滴眼液，每日2次，每次3周，双眼NB_（1/2）略有增加<ONH>，而0.5%倍他洛尔滴眼液，仅对同侧眼NB_（1/2）略有增加，而0.5%噻吗洛尔滴眼液，双眼NB_（1/2）无影响。这些<ONH>结果表明，某些β受体阻滞剂局部给药可影响视神经头循环，某些钙拮抗剂可增加视神经头血流量，这可能对治疗青光眼或研究青光眼的发病机制有意义。